News

DoD Awards $1.74 Billion Agreement to Moderna, Inc. to Secure Over 65 Million Doses of COVID-19 Vaccine for Fall Vaccinations
July 29, 2022 — On July 28, 2022, the Department of Defense (DoD), on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), awarded a $1.74 billion agreement to purchase over 65 million doses of Moderna’s COVID-19 vaccine for a fall vaccination campaign. The vaccine will target the SARS-CoV-2 Omicron subvariant viruses, as... MORE

Crystal Tyler, pharmacy technician, prepares an injection for an Operation Warp Speed patient volunteer at Brooke Army Medical Center, Fort Sam Houston, Texas, November 16, 2020. BAMC and Wilford Hall Ambulatory Surgical Center are participating in the Phase III trial to evaluate the vaccine under development by AstraZeneca as part of a national initiative to accelerate the development, production and distribution of COVID-19 vaccines, therapeutics and diagnostics.

JETT Takes Off, Now Servicing Industry with JPMs, JPLs
July 19, 2022 — Today, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) launched the Joint Enterprise Technology Tool, a web-based interface for industry members to share their business ideas and innovations with the JPEO-CBRND. Called “JETT” for short, it will serve as the front door for potential partners to connect with the right joint project managers, (JPMs) joint project leads (JPLs), program managers, and technologists for future conversations... MORE

Biden-Harris Administration secures 3.2 million doses of Novavax COVID-19 Vaccine
July 11, 2022 — Latest vaccine will provide an additional option for the American public, pending FDA Emergency Use Authorization and CDC recommendation... MORE

A servicemember sits in a yellow shirt in front of a table of red and blue testing vials. Covi

Biden-Harris Administration Secures More Than 100 Million Doses of Pfizer's Latest COVID-19 Vaccine for Fall Vaccine Campaign
June 29, 2022 — The U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense (DOD), announced an agreement to purchase more than 100 million doses of Pfizer’s COVID-19 vaccine for a fall vaccine campaign. The contract announcement follows a June 28, 2022 meeting of the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee, which recommended the inclusion of an Omicron component for COVID-19 booster vaccines in the U.S. To award the contract, the Biomedical Advanced Research and Development Authority (BARDA), part of ASPR, collaborated with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) who led this effort in partnership with the Defense Assisted Acquisition Cell (DA2) and U.S. Army Contracting Command... MORE

In the foreground a hand holding an orange sticker that says "I got my vaccine". In the background there are three medical personnel wearing personal protective equipment.

DOD Awards $79.9 Million Contract to Premix, Inc. to Onshore Production Capacity of Resin for Pipette Tips Required for COVID-19 Diagnostic Testing
May 11, 2022 — On May 5, 2022, the Department of Defense (DOD), on behalf of and in coordination with the U.S. Department of Health and Human Services (HHS), awarded a $79.9 million contract to Premix, Inc. to establish production of a plastic compound primarily used for pipette tips, which are essential to COVID-19 and other diagnostic testing efforts. Premix,... MORE

Two uniformed service members are in a tent. One wears PPE and a faceshield, while they use a nasal swab to collect a COVID-19 sample from the other Service member in uniform.

DoD Awards Contract Modifications to Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS’ One Billion Free At-Home COVID-19 Tests
March 28, 2022 — In the month of March, the Department of Defense (DoD), in coordination with the U.S. Department of Health and Human Services (HHS), awarded contract modifications to Abbott Rapid Dx North America, LLC (Orlando, Florida) and iHealth Labs Inc. (Sunnyvale, California), purchasing an additional 176.8 million over-the-counter COVID-19 test kits. The DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) led this effort in partnership with DoD’s Defense Assisted Acquisition Cell (DA2), Army Contracting Command, and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). The procurement was funded through the American Rescue Plan Act to supply critical medical resources to the nation... MORE

DOD-Supported 10mg Naloxone Autoinjector Receives FDA Approval to Treat Known or Potential Ultra-Potent Opioid Exposure
March 17, 2022 — On February 28, 2022, the FDA approved a 10mg naloxone autoinjector designed for non-medically trained users to protect service members against ultra-potent opioids. It was developed by Kaléo, Inc., in collaboration with the JPM CBRN Medical and the Chemical and Biological Defense Program. The JPM CBRN Medical’s Rapid Opioid Countermeasure System (ROCS) program has spent nearly three years developing the 10mg naloxone autoinjector as a rescue treatment to counter pharmaceutical-based agents, which are highly lethal at very low doses. The product is specifically indicated for military and chemical incident responders, and can also be used before suspected opioid exposure. ... MORE

While wearing MOPP Level 4 gear a test player prepares to use a ROCS auto-injector on a simulated causality.

DOD Awards Contracts to Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS’ One Billion Free At-Home COVID-19 Tests
February 18, 2022 — This week, the DoD, in coordination with HHS, awarded contract modifications to Roche Diagnostics Corporation and Siemens Healthineers purchasing a combined total of 138 million over-the-counter COVID-19 test kits. The JPEO-CBRND led this effort in partnership with DoD’s Defense Assisted Acquisition Cell (DA2), Army Contracting Command, and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). The procurement was funded through the American Rescue Plan Act to supply critical medical resources to the nation... MORE

American flags against a blue sky background

DOD Awards $250 Million Contract to Ology Bioservices, Inc., for Botulinum Monoclonal Antibody Advanced Development through FDA Licensure
February 10, 2022 — The JPEO-CBRND's Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) awarded Ology Bioservices, Inc. a $250 million sole source Federal Acquisition Regulation-based Indefinite Delivery/Indefinite Quantity (IDIQ) contract. Under the contract, Ology will advance the Botulinum Monoclonal Antibody (BOT MAB) product to U.S. Food and Drug Administration (FDA) licensure as a medical countermeasure (MCM), to protect the warfighter from exposure to botulinum neurotoxin (BoNT) A and B serotypes and to subsequently procure the FDA-licensed product... MORE

DOD Awards Contract to Siemens Healthineers to Purchase COVID-19 Antigen Over-the-Counter Test Kits in Support of POTUS' 500 Million Free At-Home COVID-19 Tests
January 24, 2022 — On Jan. 21, 2022, the Department of Defense (DoD), in coordination with the U.S. Department of Health and Human Services (HHS), awarded a contract to Siemens Healthineers, located in Tarrytown, New York, to procure 50 million over-the-counter COVID-19 test kits. This effort supports the president’s plan to deliver 500 million free at-home COVID-19... MORE

News Search

News Archive - Search by Year and Month

2025 (7)
2024 (40)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.

The information contained in these articles has been reviewed and approved for public release.

The appearance of hyperlinks does not constitute endorsement by the JPEO-CBRND of non-U.S. government sites or the information, products, or services contained therein. Although the JPEO-CBRND may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all the information that you may find at these locations. Such hyperlinks are provided consistent with the stated purpose of this website.